TY - JOUR
T1 - From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research
AU - Cassels, B K
AU - Bermudez, I
AU - Dajas, F
AU - Abin-Carriquiry, J A
AU - Wonnacott, S
PY - 2005/12
Y1 - 2005/12
N2 - S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.
AB - S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.
UR - http://dx.doi.org/10.1016/S1359-6446(05)03665-2
U2 - 10.1016/S1359-6446(05)03665-2
DO - 10.1016/S1359-6446(05)03665-2
M3 - Article
SN - 1359-6446
VL - 10
SP - 1657
EP - 1665
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 23-24
ER -